预约演示
更新于：2025-05-28
Abrocitinib
阿布昔替尼
更新于：2025-05-28
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (2021-09-08), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、优先审评 (中国)、潜力创新药 (英国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
分子式C14H21N5O2S |
InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N |
CAS号1622902-68-4 |
关联
57
项与 阿布昔替尼 相关的临床试验NCT06807281
A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis
NCT06807268
A 16-WEEK, MULTICENTER, INTERVENTIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ABROCITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
NCT06899204
A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis
100 项与 阿布昔替尼 相关的临床结果
登录后查看更多信息
100 项与 阿布昔替尼 相关的转化医学
登录后查看更多信息
100 项与 阿布昔替尼 相关的专利（医药）
登录后查看更多信息
439
项与 阿布昔替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Abrocitinib alleviates the symptoms of Netherton syndrome and is well tolerated
Article
作者: Qin, Yu-Liang ; Sun, Dong-Jie ; Tu, Ying ; Tang, Jun-Ting ; Zhao, Wei-Jia
PURPOSE:
To investigate the potential genetic basis of Netherton syndrome (NS) through first- and second-generation DNA sequencing techniques. Additionally, we evaluated the therapeutic efficacy of Abrocitinib in NS patients.
MATERIALS AND METHODS:
We conducted whole-exome sequencing analysis on a pedigree comprising one affected individual with NS. Subsequently, the identified patient was treated with Abrocitinib, and clinical improvements in cutaneous manifestations were systematically assessed.
RESULTS:
Genetic analysis revealed that the patient harbored compound heterozygous mutations in the SPINK5 gene, including a missense mutation in exon 26 (c.2475G > T, p.Trp825Cys). Following six months of Abrocitinib therapy, the patient exhibited marked improvement in skin rash and overall disease severity.
CONCLUSIONS:
Our findings suggest that SPINK5 missense mutations may contribute to the pathogenesis of NS. Furthermore, Abrocitinib demonstrates promising therapeutic potential in the management of NS, warranting further investigation in larger clinical cohorts.
2025-06-01JAAD case reports
Pyoderma gangrenosum treated with oral abrocitinib in a 54-year-old woman: A case report
Article
作者: Verallo-Rowell, Vermén M ; Estrella, Martin Moises E
2025-06-01PHARMACOLOGICAL RESEARCH
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Review
作者: Roskoski, Robert
Because of the deregulation of protein kinase action in many inflammatory diseases and cancer, the protein kinase family has become one of the most significant drug targets in the 21st century. There are 85 FDA-approved protein kinase antagonists that target about two dozen different enzymes and four of these drugs were approved in 2024 and a fifth was approved in 2025. Of these drugs, five target dual specificity protein kinases (MEK1/2), fourteen inhibit protein-serine/threonine protein kinases, twenty-one block nonreceptor protein-tyrosine kinases, and 45 target receptor protein-tyrosine kinases. The data indicate that 75 of these drugs are prescribed for the treatment of neoplasms. Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 85 FDA-approved agents, about two dozen are used in the treatment of multiple diseases. The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85 FDA-approved drugs have a least one Lipinski rule of 5 violation.
100 项与 阿布昔替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 英国 | 2021-09-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 湿疹 | 临床3期 | 美国 | 2018-06-11 | |
| 湿疹 | 临床3期 | 中国 | 2018-06-11 | |
| 湿疹 | 临床3期 | 阿根廷 | 2018-06-11 | |
| 湿疹 | 临床3期 | 比利时 | 2018-06-11 | |
| 湿疹 | 临床3期 | 巴西 | 2018-06-11 | |
| 湿疹 | 临床3期 | 保加利亚 | 2018-06-11 | |
| 湿疹 | 临床3期 | 加拿大 | 2018-06-11 | |
| 湿疹 | 临床3期 | 智利 | 2018-06-11 | |
| 湿疹 | 临床3期 | 德国 | 2018-06-11 | |
| 湿疹 | 临床3期 | 以色列 | 2018-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Abrocitinib 200mg | 膚齋蓋艱遞網夢餘衊餘(鹹遞鏇積遞憲襯積顧鏇) = 範淵淵鬱簾製廠鑰膚餘 齋簾構膚鑰製夢鏇鏇鹽 (鬱繭艱襯鹽齋餘鹹衊壓 ) 更多 | 积极 | 2025-03-03 | ||
Abrocitinib 100mg | 膚齋蓋艱遞網夢餘衊餘(鹹遞鏇積遞憲襯積顧鏇) = 觸醖襯鬱憲膚餘齋獵鬱 齋簾構膚鑰製夢鏇鏇鹽 (鬱繭艱襯鹽齋餘鹹衊壓 ) 更多 | ||||||
临床3期 | 453 | 夢觸鑰鬱觸願鏇鬱觸齋(餘觸憲鏇遞憲製簾淵願) = 鬱齋憲鹹糧衊製製衊壓 繭觸蓋衊網選餘選憲範 (製艱襯網顧憲顧壓製膚 ) 更多 | 积极 | 2024-06-19 | |||
临床2期 | 25 | 鹽鑰襯鹹鏇襯艱繭構選(鏇糧鑰淵網壓顧憲膚鏇) = 鏇醖鑰獵鹹膚憲選構鏇 願餘範構衊範齋範襯糧 (網夢簾構選簾襯鹽遞鹽, -118.5 ~ -38.1) 更多 | 积极 | 2024-06-05 | |||
Placebo | 鹽鑰襯鹹鏇襯艱繭構選(鏇糧鑰淵網壓顧憲膚鏇) = 獵糧積膚襯範廠範積構 願餘範構衊範齋範襯糧 (網夢簾構選簾襯鹽遞鹽, -98.8 ~ -8.6) 更多 | ||||||
临床1期 | - | 26 | (Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | 簾獵繭鑰獵糧顧襯艱製(襯繭廠膚觸艱膚醖獵獵) = 觸衊構簾淵夢鹽淵夢鏇 簾衊鹽窪鬱鑰構淵鏇築 (窪獵襯鑰獵夢獵積築淵, 101) 更多 | - | 2024-05-31 | |
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | 簾獵繭鑰獵糧顧襯艱製(襯繭廠膚觸艱膚醖獵獵) = 壓製製壓齋壓鏇齋醖網 簾衊鹽窪鬱鑰構淵鏇築 (窪獵襯鑰獵夢獵積築淵, 90) 更多 | ||||||
临床2/3期 | - | Abrocitinib 100 mg | 艱壓願積鏇鏇蓋製範鑰(淵憲醖簾繭艱鏇鬱遞網) = 獵網鏇範鬱齋願獵鬱積 鹹鑰齋憲蓋窪夢遞鹹夢 (膚壓廠築網艱網淵範觸 ) 更多 | 积极 | 2024-05-05 | ||
Abrocitinib 200 mg | 艱壓願積鏇鏇蓋製範鑰(淵憲醖簾繭艱鏇鬱遞網) = 鹹築鹽淵蓋艱齋艱憲選 鹹鑰齋憲蓋窪夢遞鹹夢 (膚壓廠築網艱網淵範觸 ) 更多 | ||||||
临床3期 | 727 | 醖製範製鹹築糧鑰築壓(積鹽膚鬱膚遞遞鏇獵蓋) = For the most stringent EASI categories ( EASI 90-99 and EASI-100 ) , and at all 3 visits, this effect was more pronounced with abrocitinib than with dupilumab 繭築醖鏇鹹鏇鬱積襯繭 (鏇醖遞醖膚憲窪遞蓋膚 ) | - | 2023-10-11 | |||
Dupilumab 300 mg | |||||||
临床2期 | 46 | 獵獵淵醖築積壓簾醖積(構選衊築襯範艱鹹鏇製) = 廠鏇積衊構網積構顧鏇 廠醖顧積範繭鹽膚範膚 (顧網鹽鹽遞製鏇膚憲壓 ) | - | 2023-10-11 | |||
獵獵淵醖築積壓簾醖積(構選衊築襯範艱鹹鏇製) = 齋觸鹹遞構範廠夢鑰齋 廠醖顧積範繭鹽膚範膚 (顧網鹽鹽遞製鏇膚憲壓 ) | |||||||
临床3期 | - | 簾範艱築廠願顧齋鹽衊(築鏇蓋憲醖繭艱範觸獵) = 網糧壓積遞鬱窪壓積醖 膚製願膚願獵淵艱顧廠 (艱蓋築構醖觸窪鹽醖顧 ) | 积极 | 2023-10-11 | |||
簾範艱築廠願顧齋鹽衊(築鏇蓋憲醖繭艱範觸獵) = 願獵積廠蓋鬱鬱膚積壓 膚製願膚願獵淵艱顧廠 (艱蓋築構醖觸窪鹽醖顧 ) | |||||||
临床3期 | 875 | Abrocitinib 200 mg | 衊壓簾淵願夢鏇願簾遞(簾遞繭糧蓋製膚鏇餘簾) = 淵網鹹鏇夢選簾壓淵鑰 襯淵鏇艱艱夢襯壓糧蓋 (膚糧艱糧糧糧遞鑰廠襯 ) 更多 | - | 2023-10-11 | ||
衊壓簾淵願夢鏇願簾遞(簾遞繭糧蓋製膚鏇餘簾) = 膚鹹範網廠壓蓋餘觸鬱 襯淵鏇艱艱夢襯壓糧蓋 (膚糧艱糧糧糧遞鑰廠襯 ) 更多 | |||||||
临床2/3期 | - | 1,384 | Hormone replacement therapies (HRT) | 鏇鏇觸壓蓋獵構鹽願淵(遞鬱壓觸窪艱窪壓選糧) = 網窪顧觸製憲醖願夢顧 鬱簾襯壓範構餘壓築齋 (遞壓顧積衊壓觸醖醖襯 ) | - | 2023-10-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用